

# **Effect of Tenapanor on Interdialytic Weight Gain in Patients on Hemodialysis**

Geoffrey A. Block MD,<sup>\*</sup> David P. Rosenbaum PhD,<sup>†</sup> Maria Leonsson-Zachrisson MD,<sup>‡</sup>  
Bergur V. Stefansson MD,<sup>‡</sup> Tina Rydén-Bergsten MSc,<sup>‡</sup> Peter J. Greasley PhD,<sup>‡</sup> Susanne A.  
Johansson MSc,<sup>‡</sup> Mikael Knutsson PhD,<sup>‡</sup> and Björn C. Carlsson MD<sup>‡</sup>

<sup>\*</sup>Denver Nephrology, Denver, Colorado


<sup>†</sup>Ardelyx Inc., Fremont, California

<sup>‡</sup>AstraZeneca R&D, Mölndal, Sweden

## **Supplementary Material**

# Supplementary Material 1

Interdialytic weight gain across the study period for the in-patient cohort



	Absolute mean IDWG (kg)						
	Baseline	Week 1	Week 2	Week 3	Week 4	Week 5	Week 6
Tenapanor	3.5±0.6	2.0±1.2	3.3±1.1	3.6±1.3	3.8±1.3	3.1±0.9	3.2±1.2
<i>n</i>	8	8	8	8	8	8	8
Placebo	4.1±1.1	3.7±1.9	3.9±0.9	4.0±1.7	3.6±1.8	3.7±1.6	3.4±1.4
<i>n</i>	8	8	8	8	8	8	8

Values are mean±standard deviation, offset for clarity, in line graph. Absolute mean weekly IDWG is shown as mean±standard deviation. IDWG, interdialytic weight gain.

## Supplementary Material 2

Proportions of patients achieving specific thresholds of IDWG reductions (out-patient cohort)

IDWG reduction threshold	Week	Treatment group	
		Tenapanor ( <i>n</i> =37), %	Placebo ( <i>n</i> =35), %
≥ 0.25 kg	1	51	43
	2	54	40
	3	57	34
	4	46	46
≥ 0.50 kg	1	32	29
	2	32	29
	3	43	23
	4	32	23
≥ 0.75 kg	1	22	26
	2	24	17
	3	32	11
	4	22	20